Actively Recruiting
Real-World Study of Glofitamab Treatment for Adults with Relapsed or Refractory Large B-cell Lymphoma
Led by The Lymphoma Academic Research Organisation · Updated on 2026-06-03
250
Participants Needed
30
Research Sites
39 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are analyzing the real-world experience of patients treated with Glofitamab for relapsed or refractory large B-cell lymphoma DLBCL. This observational study focuses on patients who participated in the French Expanded Access Programme EAP, with more than 300 treated patients and a median follow-up expected to exceed nine months. The study particularly aims to confirm the response rates of Glofitamab in patients who have previously received CAR-T therapy and to determine the best timing to start the treatment. The study includes patients who received at least one infusion of Glofitamab following pretreatment with Obinutuzumab as part of the Early Phase Access program. The treatment details are collected retrospectively from patients enrolled before November 1, 2024. The primary outcome being assessed is the best complete response rate during treatment, based on investigator evaluation using Lugano 2014 criteria at six months. Participants data will be reviewed to measure treatment effectiveness and safety, including complete metabolic response rates, progression-free survival, event-free survival, overall survival, rates of immune-related side effects like neurotoxicity and cytokine release syndrome, ICU admissions, and hospitalization events over six months. This analysis helps to better understand Glofitamabs performance in a large real-world patient group, with continued monitoring of outcomes and adverse events during the follow-up period.
CONDITIONS
Brief Title
Glofitamab in Real Life
Research Team
P
PROJECT MANAGER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here